Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- MHLW Issues Notification on Drug Criteria for Optimal Use Guidelines
September 20, 2017
- Japan Drug Spending Logs 1st Fall in FY2016
September 19, 2017
- MHLW Begins Discussions towards Submission of Bill to Amend Pharma Law in 2019: Official
September 19, 2017
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
- Chuikyo Working to Craft ICER Yardstick for Pilot CEA Scheme; Shiroiwa Study Leading Candidate among WTP Cost Surveys?
September 14, 2017
- Chuikyo Ponders How to Deal with ICER for Products with Multiple Indications
September 14, 2017
- Samurai Biotech Association Calls for NHI Price Increases When Sales Fall Below Forecasts: Chuikyo
September 14, 2017
- JGA President Sees Reduction in Number of Generic Drug Makers as “Inevitable”: Chuikyo
September 14, 2017
- With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
September 14, 2017
- JPWA Expresses Concern Over Price Renegotiations, Calls for Guidelines to Curb Practice
September 14, 2017
- (Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW to Notify of Criteria for Drugs Subject to Optimal Use Guidelines in Mid-September
September 13, 2017
- Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW Calls for Reduction in Maximum Administration Period and Total Dosage for Feron
September 13, 2017
- MOF Budget Examiner Questions Price Maintenance Premium, Says Its Impact Amounts to Over 253 Billion Yen in FY2017
September 12, 2017
- MHLW to Draft GL on Use of Real World Data in Application Filings to Promote Development of Drugs for Rare Diseases
September 12, 2017
- Kyorin’s Dimethyl Sulfoxide Gets Orphan Status in Japan
September 11, 2017
- MHLW Panel Backs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med and More
September 11, 2017
- Opdivo Clears MHLW Panel for 3rd Line Use in Gastric Cancer, Keytruda to Lose Sakigake Status
September 8, 2017
- Social Security Council Begins Discussion on Basic Policy for FY2018 Reimbursement Reform
September 8, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…